Molecular pathology has significantly matured over the past decade to establish itself as a discipline in its own right. Patient diagnosis, prognosis, management and care have been influenced by molecular pathology testing algorithms on a global scale. Whether it pertains to carrier status of deleterious genes, diagnosis by molecular techniques, assessment of appropriate remission post treatment, parentage or forensics testing - molecular pathology continues to increase its presence and influence in the diagnostic laboratory armamentarium. Furthermore, intellectualization and proprietization of molecular pathology with respect to the discovery of new genes and or new techniques continues to pose new challenges of test ownership, legalities, liabilities, widespread acceptance and utility. This issue of Laboratory Clinics seeks to provide selective state of the art understanding of molecular pathology with respect to its relationship to key pathology disciplines as well as the current challenges and promise for the future

This issue of Hematology/Oncology Clinics is focused on Hodgkin's Lymphoma and covers such topics as First HRS-cell line L428 and the detection of the CD-30 Antigen , "Normal" CD30-B-lymphocytes, CD-30-Antigen, Combination-Chemo-Radiotherapy, Early intensification (escBEACOPP), Customized/Targeted Therapy, and more.

This issue of Hematology/Oncology Clinics, guest edited by Dr. Elliott Vichinsky, is devoted to Sickle Cell Disease, and focuses on pathophysiology of hemoglobinopathies, therapeutic targets, and new approaches to correcting ineffective erythropoiesis and iron dysregulation. Articles in this issue include Polymerization and red cell membrane changes; Overview on reperfusion injury in the pathophysiology of SCD; Regulation of ineffective erythropoiesis in iron metabolism; Altering oxygen affinity; Cellular adhesion and the endothelium; Arginine therapy; Role of the hemostatic system on SCD pathophysiology and potential therapeutics; Adenosine signaling and novel therapies; New approaches to correcting ineffective erythropoiesis and iron dysregulation; New approaches to correcting ineffective erythropoiesis and iron dysregulation; Fetal hemoglobin induction; Gene therapy for hemoglobinopathies; and Oxidative injury and the role of antioxidant therapy.

This issue focuses on Sarcoma in areas such as: Gastrointestinal Stromal Tumors: Risk assessment and adjuvant therapy, Gastrointestinal Stromal Tumors: Management of metastatic disease and emerging therapies, Liposarcoma, Leiomyosarcoma, Update in treatment and targets in cartilage and bone tumors, Update in treatment and targets in Ewing sarcoma, Angiosarcoma and Epithelioid Hemangioendothelioma, Emerging therapies for sarcoma, and Treatment of localized sarcomas.

This issue, focusing on Breast Cancer, includes topics such as: Radiation Therapy for DCIS, Axillary dissection, Pathology in the age of personalized breast cancer treatment:, Clinical implications for breast cancer subsets defined by molecular diagnostics, Management of CNS Metastases in Breast Cancer, Endocrine therapy for advanced breast cancer, Targeting the PI3K pathway in breast cancer, Treating the Older Breast Cancer Patient, Adjuvant chemotherapy in the age of targeted treatment, and Novel radiotherapy approaches for early breast cancer

Hematology and Coagulation: A Comprehensive Review for Board Preparation, Certification and Clinical Practice, Second Edition, takes a practical and easy-to-read approach to understanding hematology and coagulation at an appropriate level for both board preparation and refresher courses. The book bridges the gap between large textbooks and medical technology books written for laboratory technicians, providing the sufficient background in genetics, toxicology and immunology that residents and medical students need to know in order to become successful physicians. Readers will use this quick reference to understand how tests are performed and how to interpret results. This clear and easy-to-read presentation of core topics and detailed case studies illustrates the application of hematopathology on patient care.

This issue of Hematology/Oncology Clinics is guest edited by Dr. A. Koneti Rao and focuses on Disorder of the Platelets. Article titles include: Mechanisms of Platelet Activation and Inhibition, Testing Platelet Function, Clinical Implications of Platelet Genomics and Proteomics, Congenital Thrombocytopenias, Immune Thrombocytopenias, Heparin Induced Thrombocytopenia, and Functional defects: Chronic granulomatous disease (CGD) and beyond

This issue focuses on three disease sections: Diabetes, Hematology and Coagulation, and covers diagnostic and management issues during pregnancy of selected topics in each section. The chapters cover new concepts, evolving management and important impacts on the mother and unborn child.

This issue of Hematology/Oncology Clinics is edited by Dr. Jennifer Brown and focuses on Chronic Lymphocytic Leukemia. Article topics include: What Have Recent Genomic Advances Taught us About CLL?, Biology of CLL in Different Microenvironments, What is the Significance of Stereotyped BCRs in CLL?, Understanding Immunodeficiency in CLL, MBL vs CLL: How Important is the Distinction?, Risk Stratification of CLL in 2012, Minimal Residual Disease Measurement in CLL, The BTK Inhibitor PCI-32765 in CLL, and Evolving Role of Stem Cell Transplantation in CLL

This issue of Hematology/Oncology Clinics is guest edited by Dr. Christoph Klein and focuses on the topic of Neutropenia. Article titles include: Homeostasis and migration of neutrophil granulocytes, Granulocyte-colony Stimulating Factor (G-CSF) receptor signaling, New Granulocyte-colony Stimulating Factor (G-CSF) Receptor Signaling Pathways, Neutrophil elastase (ELANE) - Genetics and Pathophysiology, Autosomal recessive variants of Severe congenital neutropenia (SCN), Leukocyte Adhesion Deficiency (LAD), and Genotype-phenotype correlations in Severe congenital neutropenia (S

This open access book has been written by ten Belgian health care professionals, nurses, university professors and doctors specializing in palliative care and ethicists who, together, raise questions concerning the practice of euthanasia. They share their experiences and reflections born out of their confrontation with requests for euthanasia and end-of-life support in a country where euthanasia has been decriminalized since 2002 and is now becoming a trivial topic.Far from evoking any militancy, these stories of life and death present the other side of a reality needs to be evaluated more rigorously.Featuring multidisciplinary perspectives, this though-provoking and original book is intended not only for caregivers but also for anyone who questions the meaning of death and suffering, as well as the impact of a law passed in 2002. Presenting real-world cases and experiences, it highlights the complexity of situations and the consequences of the euthanasia law.This book appeals to palliative care providers, hematologists, oncologists, psychiatrists, nurses and health professionals as well as researchers, academics, policy-makers, and social scientists working in health care. It is also a unique resource for those in countries where the decriminalization of euthanasia is being considered. Sometimes shocking, it focuses on facts and lived experiences to challenge readers and offer insights into euthanasia in Belgium.

Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies in MPNs; Role of novel mutations in MPN pathogenesis and outcome; Role of JAK inhibitors in MPN treatment; Animal Models of MPNs; and Role of Germline Genetic Factors in MPN Pathogenesis.

2014 BMA Medical Book Awards Highly Commended in Internal Medicine category! This textbook on haematology in the Illustrated Colour Text series is suitable for medical students, junior doctors and others needing a concise and practical introduction to the subject. Concise and manageable coverage of the major blood diseases and their treatment. Does not overload the reader with science, unlike some competing books. Focus is on the haematology patient and on the practical aspects of the subject. Makes use of the attractive features of the ICT series - double page spreads, lots of colour illustrations, summary boxes. Updating to take account of recenty developments in stem cell biology. Increased emphasis on genomic and proteomic techniques in the diagnosis of haematological malignancy. Use of new imaging techniques including MRI and PET. Description of advances in treatment of leukaemia and lymphoma and in diagnosis and management of patients with thrombophilia and venous thrombosis. Development of new antimicrobial agents in management of immunosuppressed patients with infection. New double page spread on palliative care of patients with blood disorders. New illustrations.

Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects, Third Edition, is the only pocket-sized, quick reference for pathology and transfusion medicine residents and fellows. It covers all topics in transfusion medicine and clinical and laboratory-based coagulation. Chapters are organized by multiple hierarchical headings and are supplemented with up to 10 suggested reading citations. This single handbook covers all the topics required to meet the goals of a major program in transfusion medicine and clinical coagulation. Changes to this edition include the latest AABB standards and new chapters focused on a wider range of specific populations requiring blood and related products. Coverage includes essential updates on peripheral blood and bone marrow hematopoietic progenitor cells, as well as cord blood banking and regenerative medicine. The authors also examine advances in therapeutic apheresis and new cellular therapies.

The Oxford Handbook of Clinical Haematology provides core and concise information on the entire spectrum of blood disorders affecting both adults and children. Updated for its fourth edition, it includes all major advances in the specialty, including malignant haematology, haemato-oncology, coagulation, transfusion medicine, and red cell disorders, with a brand new chapter on rare diseases. Practically focused, and specifically designed for ease-of-use, and rapid access to the information you need, this handbook is an indispensable resource on all aspects of haematology for all trainee doctors, nurses, technicians, and research professionals. The handbook is divided into clinical approach and disease-specific areas. The clinical approach section outlines various symptoms and signs in patients with blood disease to enable the reader to formulate a sensible differential diagnosis beofre embarking on investigation and treatment. The disease-specific section is written by four authors whose expertise covers the whole breadth of diseases included in the book. All authors have contributed to national guidelines (e.g. British Committee for Standards in Haematology, BCSH) and are experts in the evidence base that exists for each topic. The Oxford Handbook of Clinical Haematology offers a concise and logical approach to caring for patients with diseases of the blood.

Topics in this issue?include: Targeting IGF-1R; Tyrosine Kinase Inhibitors in Lung Cancer; Targeting mTOR; Targeting Hedgehog; Mitotic Inhibitors; Topoisomerase I Inhibitors; and New Strategies and Drugs Inhibiting Folate Pathways.

Topics in this issue?include: Why does my patient have leukocytosis?; Why Is My Patient Neutropenic?; Does My Patient with a Serum Monoclonal Spike have Multiple Myeloma?; DVT and Pulmonary Embolism; Why Does My Patient Have Lymphadenopathy/Splenomegaly?; and Why Does My Patient have Thrombocytopenia?

Topics for this issue will include: CLL: ? A Historical Perspective; Incidence & Epidemiology; Biology, Molecular Biology & Cytogenetics of CLL; What does the status of smatic hypermutations in IGVH genes tell us about the origin of CLL?; What does the status of ZAP-70 tell us about the biology of CLL?; and Approach to initial therapy: When to start therapy?

Dr. Talpaz has assembled top experts to write state-of-the art reviews on the management of chronic myelogenous leukemia. Some of the articles that will be of most interest include Selection of Therapy: Rational Decisions Based on Molecular Events; Is There a Potential Cure for CML in Current Therapies?; Hurdles Toward a Cure for CML: The CML Stem Cell; The CML Stem Cell in the Chronic and Advanced Disease; CML Disease Progression; Management of Ph+ ALL and CML Blast Crisis; BMT in CML in the Era of Targeted Therapy; Pharmacoeconomics: The Cost of Staying Alive; and The Significance of CML Prognostic Factors in the Era of Targeted Therapy.

Topics?in this issue?include: Genetic Risk and Gynecologic Cancer; Current Management of Preinvasive Cervical Neoplasia; Current Surgical Management of Cervical Neoplasia; Current Surgical Management of Ovarian Cancer; Current Management of Trophoblastic Disease; and New Developments in Radiation Management and Gynecologic Cancers.

Dr. Connors has provided comprehensive coverage of the pregnant patient with hematologic disorders--from management in early pregnancy to delivery. Hematologic disorders covered include anemia, myeloproliferative disorders, von Willebrand disease, leukemia and lymphoma, thrombochytopenia, and thrombophilia. Other important topics in this issue include anesthesia in the pregnant patient with a hematologic disorder as well as transfusion medicine.

This issue addresses hypercoagulable states, such as antiphospholipid antibody syndrome, cancer-associated thrombosis, and coagulopathy associated with sepsis.? New anticoagulants discussed include oral Xa inhibitors, oral IIa inhibitors, agents for the treatment of HIT, and use of low molecular weight heparin to improve survival in cancer patients.

Better therapy of acute leukemias depends ultimately on better understanding of the distinction between leukemic and normal progenitor cells. This hugely important new book describes the current knowledge of acute leukemia biology and discusses new classification systems that have arisen as a result of emerging insights into pathogenesis. Estey, Faderl and Kantarjian, who all work at the respected Anderson Cancer Center in Houston, Texas, USA, examine in detail advances in the treatment of particular types of acute leukemia. Their book also covers the management of acute leukemia in general as well as the development of new therapies. This book will be extremely useful to clinicians.